Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma Between 2012 and 2016, Treated According to Routine Clinical Practice in Spain

NCT03602755 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03602755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03602755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma Between 2012 and 2016, Treated According to Routine Clinical Practice in Spain
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
July 19, 2018
Completion date
January 18, 2019
Enrollment
706 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma